



# **Mometasone Ointment Formulation**

Version 2.2	Revision Date: 09.04.2021		DS Number: 758836-00009	Date of last issue: 10.10.2020 Date of first issue: 14.06.2017		
SECTION	SECTION 1: Identification of the substance/mixture and of the company/undertaking					
<b>1.1 Produc</b> Trade	t identifier		Mometasone Oin	tment Formulation		
		ho c				
	the Sub-	ne s		ure and uses advised against		
stance/Mixture		•	Tharmaceutical			
1.3 Details of the supplier of the safety data sheet						
Compa	any	:	Organon & Co.			
			30 Hudson Street 07302 Jersev Cit	y, New Jersey, U.S.A		
				,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
Teleph	none	:	551-430-6000			
	address of person asible for the SDS	:	EHSSTEWARD@	organon.com		
1.4 Emergency telephone number						

215-631-6999

## **SECTION 2: Hazards identification**

## 2.1 Classification of the substance or mixture


### Classification (REGULATION (EC) No 1272/2008)

Skin irritation, Category 2	H315: Causes skin irritation.
Eye irritation, Category 2	H319: Causes serious eye irritation.
Long-term (chronic) aquatic hazard, Cat-	H411: Toxic to aquatic life with long lasting effects.
egory 2	

#### 2.2 Label elements

### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms	:	
Signal word	:	Warning
Hazard statements	:	<ul><li>H315 Causes skin irritation.</li><li>H319 Causes serious eye irritation.</li><li>H411 Toxic to aquatic life with long lasting effects.</li></ul>
Precautionary statements	:	Prevention:P264Wash skin thoroughly after handling.P273Avoid release to the environment.





# **Mometasone Ointment Formulation**

Version 2.2	Revision Date: 09.04.2021	SDS Number: 1758836-00009	Date of last issue: 10.10.2020 Date of first issue: 14.06.2017
		P280 Wear prot	ective gloves/ eye protection/ face protection.
		Response:	
		P332 + P313 If attention.	skin irritation occurs: Get medical advice/
		P337 + P313 If attention. P391 Collect sp	eye irritation persists: Get medical advice/

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

## **SECTION 3: Composition/information on ingredients**

### 3.2 Mixtures

### Components

Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)
	Index-No.		
	Registration number		
2-Methyl-2,4-pentanediol	107-41-5	Skin Irrit. 2; H315	>= 10 - < 20
	203-489-0	Eye Irrit. 2; H319	
	603-053-00-3		
Mometasone	83919-23-7	Repr. 1B; H360Df	>= 0.1 - < 0.25
		STOT RE 2; H373	
		(Immune system,	
		Liver, Kidney, Skin)	
		Aquatic Chronic 1; H410	
		M-Factor (Chronic	
		aquatic toxicity): 100	

For explanation of abbreviations see section 16.

according to Regulation (EC) No. 1907/2006



# **Mometasone Ointment Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.2	09.04.2021	1758836-00009	Date of first issue: 14.06.2017

### **SECTION 4: First aid measures**


4.1 Description of first aid measures				
General advice :	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.			
Protection of first-aiders :	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).			
If inhaled :	If inhaled, remove to fresh air. Get medical attention.			
In case of skin contact :	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.			
In case of eye contact :	In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.			
If swallowed :	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.			
4.2 Most important symptoms and effects, both acute and delayed				
Risks :	Causes skin irritation. Causes serious eye irritation.			

### 4.3 Indication of any immediate medical attention and special treatment needed Treatmen

nt	:	Treat symptomatically and supportively.
ni	•	rreat symptomatically and supportively.

## **SECTION 5: Firefighting measures**

5.1 Extinguishing media		
Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.





# **Mometasone Ointment Formulation**

Vers 2.2	sion	Revision Date: 09.04.2021		S Number: 58836-00009	Date of last issue: 10.10.2020 Date of first issue: 14.06.2017
5.2 \$	Special	hazards arising from	the	e substance or mix	kture
	Specific hazards during fire- fighting		:		n explosive mixtures with air. Soustion products may be a hazard to health.
	Hazard ucts	ous combustion prod-	:	Carbon oxides	
5.3	Advice	for firefighters			
	Special for firef	l protective equipment ighters	:		e, wear self-contained breathing apparatus. ective equipment.
	Specific ods	c extinguishing meth-	:	cumstances and t Use water spray t	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do

## **SECTION 6: Accidental release measures**

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	: Use personal protective equipment.
	Follow safe handling advice (see section 7) and personal pro-
	tective equipment recommendations (see section 8).

#### 6.2 Environmental precautions

Environmental precautions	: Avoid release to the environment.
	Prevent further leakage or spillage if safe to do so.
	Retain and dispose of contaminated wash water.
	Local authorities should be advised if significant spillages
	cannot be contained.

#### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up	: Sweep up or vacuum up spillage and collect in suitable con- tainer for disposal. Local or national regulations may apply to releases and dis- posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter- mine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
-------------------------	--

#### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

### **SECTION 7: Handling and storage**

### 7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

according to Regulation (EC) No. 1907/2006



# **Mometasone Ointment Formulation**

Versic 2.2	on	Revision Date: 09.04.2021		DS Number: /58836-00009	Date of last issue: 10.10.2020 Date of first issue: 14.06.2017
A	Advice	otal ventilation on safe handling e measures	: :	If sufficient ventilation. Do not get on skii Do not swallow. Do not get in eye Wash skin thorout Handle in accorda practice, based of sessment Keep container tig Take care to prevent environment. If exposure to che flushing systems place. When usin nated clothing be The effective ope engineering contra appropriate dego	s. Ighly after handling. ance with good industrial hygiene and safety n the results of the workplace exposure as- ghtly closed. Yent spills, waste and minimize release to the emical is likely during typical use, provide eye and safety showers close to the working g do not eat, drink or smoke. Wash contami- fore re-use. ration of a facility should include review of rols, proper personal protective equipment, wning and decontamination procedures, e monitoring, medical surveillance and the
7.2 Co	onditi	ons for safe storage,	inc	luding any incom	patibilities
Requirements for storage areas and containers		:	Keep in properly	labelled containers. Keep tightly closed. nce with the particular national regulations.	
А	Advice	on common storage	:	Do not store with Strong oxidizing a Organic peroxide Explosives Gases	

## 7.3 Specific end use(s)

Specific use(s) : No data available

### **SECTION 8: Exposure controls/personal protection**

### 8.1 Control parameters

### **Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis	
Petrolatum	8009-03-8	OELV - 8 hrs (TWA) (inhalable fraction)	5 mg/m3	IE OEL	
	Further information: Where no specific short-term exposure limit is listed, a figure three times the long-term exposure limit value should be used				
2-Methyl-2,4- pentanediol	107-41-5	OELV - 15 min (STEL)	25 ppm 125 mg/m3	IE OEL	
Propylene glycol monostearate	1323-39-3	OELV - 8 hrs (TWA)	10 mg/m3	IE OEL	



according to Regulation (EC) No. 1907/2006

# Mometasone Ointment Formulation

Version 2.2	Revision Da 09.04.2021		Number: 836-00009	 e of last issue: 10.10.2 e of first issue: 14.06.2	
Mome	tasone	83919-23-7	TWA	1 µg/m3 (OEB 4)	Internal
		Further inform	ation: Skin		
V		Wipe limit	10 µg/100 cm²	Internal	

### Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health ef- fects	Value
2-Methyl-2,4- pentanediol	Workers	Inhalation	Long-term systemic effects	44.4 mg/m3
	Workers	Inhalation	Long-term local ef- fects	49 mg/m3
	Workers	Inhalation	Acute local effects	98 mg/m3
	Workers	Skin contact	Long-term systemic effects	42 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	7.8 mg/m3
	Consumers	Inhalation	Long-term local ef- fects	25 mg/m3
	Consumers	Inhalation	Acute local effects	49 mg/m3
	Consumers	Skin contact	Long-term systemic effects	15 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	1.5 mg/kg bw/day

### Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Petrolatum	Oral (Secondary Poisoning)	9.33 mg/kg food
2-Methyl-2,4-pentanediol	Fresh water	0.429 mg/l
	Marine water	0.043 mg/l
	Freshwater - intermittent	4.29 mg/l
	Sewage treatment plant	20 mg/l
	Fresh water sediment	1.59 mg/kg dry weight (d.w.)
	Marine sediment	0.159 mg/kg dry weight (d.w.)
	Soil	0.066 mg/kg dry weight (d.w.)

#### 8.2 Exposure controls

#### **Engineering measures**

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

:

#### Personal protective equipment

Eye protection

Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

according to Regulation (EC) No. 1907/2006



# **Mometasone Ointment Formulation**

Version 2.2	Revision Date: 09.04.2021	SDS Number: 1758836-00009	Date of last issue: 10.10.2020 Date of first issue: 14.06.2017			
Hand protection		mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.				
Material		: Chemical-resistant gloves				
Remarks Skin and body protection		Additional body task being perfo posable suits) t	r laboratory coat. garments should be used based upon the ormed (e.g., sleevelets, apron, gauntlets, dis- o avoid exposed skin surfaces. e degowning techniques to remove potentially			
Respiratory protection Filter type		: If adequate loca sure assessme ommended guid Equipment sho	al exhaust ventilation is not available or expo- nt demonstrates exposures outside the rec- delines, use respiratory protection. uld conform to I.S. EN 14387 culates and organic vapour type (A-P)			

## **SECTION 9: Physical and chemical properties**

### 9.1 Information on basic physical and chemical properties

Physical state Colour Odour Odour Threshold	::	ointment white to off-white No data available No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling	:	No data available
range Flammability (solid, gas)	:	Not classified as a flammability hazard
Flammability (liquids)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	> 93.3 °C
Auto-ignition temperature	:	No data available
Decomposition temperature Decomposition tempera- ture pH	:	No data available No data available
Viccosity		

according to Regulation (EC) No. 1907/2006




air.

# **Mometasone Ointment Formulation**

Vers 2.2	sion	Revision Date: 09.04.2021		0S Number: 58836-00009	Date of last issue: 10.10.2020 Date of first issue: 14.06.2017		
	Vise	cosity, kinematic	:	No data availabl	e		
		ity(ies) ter solubility	:	No data availabl	e		
		on coefficient: n- I/water	:	No data available			
		r pressure	:	No data available	e		
	Relativ	e density	:	: No data available			
	Density Relative vapour density Particle characteristics Particle size		:	No data available	9		
			:	No data available	9		
			:	No data availabl	9		
9.2 (	Other i	nformation					
	Explos	ives	:	Not explosive			
	Oxidizi	ng properties	:	The substance of	r mixture is not classified as oxidizing.		
	Evapo	ration rate	:	No data available	9		
	Molecu	ular weight	:	No data availabl	9		

## **SECTION 10: Stability and reactivity**

10.1 Reactivity	
Not classified as a reactivity	/ hazard.
10.2 Chemical stability	
Stable under normal condition	ions.
10.3 Possibility of hazardous r	reactions
Hazardous reactions	: Vapours may form explosive mixture with Can react with strong oxidizing agents.
10.4 Conditions to avoid	
Conditions to avoid	: None known.
10.5 Incompatible materials	
Materials to avoid	: Oxidizing agents
10.6 Hazardous decomposition	n products
No hazardous decompositic	on products are known.





# **Mometasone Ointment Formulation**

Version	Revision Date: 09.04.2021	SDS Number:	Date of last issue: 10.10.2020
2.2		1758836-00009	Date of first issue: 14.06.2017

## **SECTION 11: Toxicological information**

## 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Skin contact exposure Ingestion Eye contact

## Acute toxicity

Not classified based on available information.

#### **Components:**

# **2-Methyl-2,4-pentanediol:**

Acute oral toxicity	•	LD50 (Rai). > 2,000 mg/kg
Acute dermal toxicity	:	LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 402 Assessment: The substance or mixture has no acute dermal toxicity

#### Mometasone:

Mometasone:		
Acute oral toxicity	:	LD50 (Rat): > 2,000 mg/kg
		LD50 (Mouse): > 2,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 3.3 mg/l Exposure time: 4 h Test atmosphere: dust/mist Remarks: No mortality observed at this dose.
		LC50 (Mouse): > 3.2 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute toxicity (other routes of administration)	:	LD50 (Rat): 300 mg/kg Application Route: Subcutaneous Symptoms: Breathing difficulties
Skin corrosion/irritation Causes skin irritation.		
Components:		
<b>2-Methyl-2,4-pentanediol:</b> Result Remarks	:	Skin irritation Based on harmonised classification in EU regulation 1272/2008, Annex VI
<b>Mometasone:</b> Species Result	:	Rabbit No skin irritation

Version

according to Regulation (EC) No. 1907/2006

Revision Date:



Date of last issue: 10.10.2020

# **Mometasone Ointment Formulation**

SDS Number:

	Revision Date: 09.04.2021	SDS Number: 1758836-00009	Date of first issue: 10.10.2020 Date of first issue: 14.06.2017							
Serio	ous eye damage/eye	irritation								
Caus	Causes serious eye irritation.									
<u>Com</u>	Components:									
2-Met	thyl-2,4-pentanediol	:								
Speci	ies	: Rabbit								
Resu	lt	: Irritation to e	yes, reversing within 21 days							
Mom	etasone:									
Speci	ies	: Rabbit								
Resu		: No eye irrita	tion							
Resp	iratory or skin sensi	tisation								
	sensitisation									
	lassified based on ava									
•	iratory sensitisation lassified based on ava									
	iassified based on ava ponents:									
	thyl-2,4-pentanediol									
Test		: Maximisation	n Test							
	sure routes	: Skin contact								
Speci		: Guinea pig								
Metho	bc	: OECD Test	Guideline 406							
Resu	lt	: negative								
Mom	etasone:									
Test <sup>-</sup>	Туре	: Maximisation	n Test							
	sure routes	: Dermal								
Speci		: Guinea pig								
Asses Resu	ssment		use skin sensitisation.							
Rema		: negative · The results of	of a test on guinea pigs showed this substance							
Ttorne			kin sensitiser.							
Germ	cell mutagenicity									
	lassified based on ava	ailable information.								
<u>Com</u>	ponents:									
	thyl-2,4-pentanediol									
Geno	toxicity in vitro	: Test Type: E Result: nega	Bacterial reverse mutation assay (AMES) tive							
			n vitro mammalian cell gene mutation test CD Test Guideline 476 tive							
		Test Type: C	Chromosome aberration test in vitro							
		10 /	22							

according to Regulation (EC) No. 1907/2006



ersion 2	Revision Date: 09.04.2021		DS Number: 58836-00009	Date of last issue: 10.10.2020 Date of first issue: 14.06.2017
			Result: negative	
Mome	etasone:			
-	toxicity in vitro	:	Test Type: Bacte Result: negative	rial reverse mutation assay (AMES)
				nosomal aberration nese hamster lung cells
				nosomal aberration nese hamster ovary cells
			Test Type: Mouse Result: negative	e Lymphoma
Geno	toxicity in vivo	:	Test Type: Micro Species: Mouse Application Route Result: negative	
			Test Type: Chron Species: Rat Cell type: Bone n Result: negative	nosomal aberration narrow
			Test Type: unsch Species: Rat Cell type: Liver co Result: negative	eduled DNA synthesis assay ells
Germ sessn	cell mutagenicity- As- nent	:	Weight of eviden cell mutagen.	ce does not support classification as a germ
	nogenicity assified based on availa	ablo	information	
	oonents:		information.	
	etasone:			
Speci Applic	es cation Route sure time	:	Rat Inhalation 2 Years 0.067 mg/kg body negative	y weight
	cation Route sure time	:	Mouse Inhalation 19 Months 0.160 mg/kg body negative	y weight

according to Regulation (EC) No. 1907/2006



Versi 2.2	ion	Revision Date: 09.04.2021		0S Number: 58836-00009	Date of last issue: 10.10.2020 Date of first issue: 14.06.2017
	-	<b>Juctive toxicity</b> ssified based on availa	able	information.	
	Compo	onents:			
	2-Meth	yl-2,4-pentanediol:			
	Effects	on fertility	:	Test Type: Repro- test Species: Rat Application Route Method: OECD To Result: negative	
	Effects ment	on foetal develop-	:	Test Type: Embry Species: Rat Application Route Method: OECD To Result: negative	
	Momet	asone:			
	Effects	on fertility	:	Symptoms: Reduce weight	
	Effects ment	on foetal develop-	:	Species: Mouse Application Route Embryo-foetal tox	o-foetal development : Subcutaneous icity: LOAEL: 0.06 mg/kg body weight xic effects., Teratogenicity and developmen-
				Species: Rat Application Route	icity: LOAEL: 0.3 mg/kg body weight
				Species: Rabbit Application Route Embryo-foetal tox	ro-foetal development : Dermal icity: LOAEL: 0.15 mg/kg body weight betal toxicity, Malformations were observed.
				Species: Rat Application Route	icity: LOAEL: 0.15 mg/kg body weight
				Test Type: Embry	o-foetal development

according to Regulation (EC) No. 1907/2006



ersion 2	Revision Date: 09.04.2021	SDS Number: 1758836-00009	Date of last issue: 10.10.2020 Date of first issue: 14.06.2017
Reproductive toxicity - As- sessment		animal expe	nce of adverse effects on development, based or priments., Some evidence of adverse effects on ion and fertility, based on animal experiments.
	<b>Γ - single exposure</b> lassified based on ava	lable information.	
<u>Com</u>	ponents:		
<b>Mom</b> Rema	<b>etasone:</b> arks	: Based on av	vailable data, the classification criteria are not me
	<b>Γ - repeated exposure</b> lassified based on ava		
<u>Com</u>	ponents:		
Mom	etasone:		
Targe	sure routes et Organs ssment	: Immune sys	lust/mist/fume) tem, Liver, Kidney, Skin damage to organs through prolonged or repeate
Repe	eated dose toxicity		
<u>Com</u>	ponents:		
2-Me	thyl-2,4-pentanediol:		
Spec	• • •	: Rat	
NOA		: >= 450 mg/l	κg
	cation Route sure time	: Ingestion : 90 Days	
Meth			Guideline 408
Mom	etasone:		
Spec		: Rat	
NOA		: 0.005 mg/kg	)
LOAE		: 0.3 mg/kg	
	cation Route sure time	: Oral : 30 d	
	et Organs		es, Liver, Adrenal gland, Skin, thymus gland
	ies	: Dog	
Spec		· • • • • • • • • • • • • • • • • • • •	
LÒAE	EL	: 0.5 mg/kg	
LOAE Appli		: 0.5 mg/kg : Oral : 30 d	

Mometasone:

Remarks

according to Regulation (EC) No. 1907/2006



# **Mometasone Ointment Formulation**

Version 2.2	Revision Date: 09.04.2021	SDS Nu 1758836		Date of last issue: 10.10.2020 Date of first issue: 14.06.2017
Expo		: inha : 90 d : Adre		ungs, Lymph nodes, spleen, Bone marrow,
Expo		: inha : 90 d : Adre		ungs, Lymph nodes, spleen, Bone marrow,
-	ration toxicity lassified based on avail	able inforn	nation.	
Com	ponents:			
	<b>etasone:</b> pplicable			
1.2 Infor	mation on other hazar	ds		
Endo	crine disrupting prop	erties		
Prod	uct:			
Asses	ssment	ered REA (EU)	to have end CH Article 5	nixture does not contain components consid- locrine disrupting properties according to 7(f) or Commission Delegated regulation or Commission Regulation (EU) 2018/605 at higher.
Expe	rience with human ex	posure		
Com	ponents:			
	thyl-2,4-pentanediol: contact		et Organs: E ptoms: Irrita	
Mom	etasone:			
Inhala	ation	pirat	ory tract infe	gic rhinitis, Headache, pharyngitis, upper res ection, sinusitis, oral candidiasis, Back pain, pain, immune system effects, indigestion
Skin o	contact			natitis, Itching
Furth	er information			
<u>Com</u>	ponents:			

: Dermal absorption possible

according to Regulation (EC) No. 1907/2006



# Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.2	09.04.2021	1758836-00009	Date of first issue: 14.06.2017

## **SECTION 12: Ecological information**

## 12.1 Toxicity

Components:		
<b>2-Methyl-2,4-pentanediol:</b> Toxicity to fish	:	LC50 (Gambusia affinis (Mosquito fish)): 8,510 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Ceriodaphnia dubia (water flea)): 2,800 mg/l Exposure time: 48 h
Toxicity to algae/aquatic plants	:	ErC50 (Pseudokirchneriella subcapitata (green algae)): > 429 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
		EC10 (Pseudokirchneriella subcapitata (green algae)): > 429 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to microorganisms	:	NOEC : 200 mg/l Exposure time: 10 d
Mometasone:		
Toxicity to fish	:	LC50 (Menidia beryllina (Silverside)): 0.11 mg/l Exposure time: 96 h Remarks: No toxicity at the limit of solubility
		LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l Exposure time: 7 d Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 5 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: No toxicity at the limit of solubility
		EC50 (Americamysis): > 5 mg/l Exposure time: 96 h Method: US-EPA OPPTS 850.1035 Remarks: No toxicity at the limit of solubility
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility

according to Regulation (EC) No. 1907/2006



Version 2.2	Revision Date: 09.04.2021	DS Number: Date of last issue: 10.10. 758836-00009 Date of first issue: 14.06.	
To	xicity to microorganisms	EC50 : > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility	
		NOEC : 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility	
To: icit	xicity to fish (Chronic tox- y)	NOEC: 0.00014 mg/l Exposure time: 32 d Species: Pimephales promelas (fathead mir Method: OECD Test Guideline 210	inow)
aqı	xicity to daphnia and other uatic invertebrates (Chron- oxicity)	NOEC: 0.34 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211 Remarks: No toxicity at the limit of solubility	
	Factor (Chronic aquatic icity)	100	
12.2 Pe	rsistence and degradabil	,	
<u>Co</u>	mponents:		
2-N	lethyl-2,4-pentanediol:		
Bio	degradability	Result: Readily biodegradable. Biodegradation: 81 % Exposure time: 28 d Method: OECD Test Guideline 301F	
Мо	metasone:		
Bio	degradability	Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 28 d Method: OECD Test Guideline 314	
Sta	bility in water	Hydrolysis: 50 %(12 d) Method: OECD Test Guideline 111	
12.3 Bio	paccumulative potential		
<u>Co</u>	mponents:		
Pa	<b>lethyl-2,4-pentanediol:</b> rtition coefficient: n- anol/water	log Pow: 0 Remarks: Calculation	

according to Regulation (EC) No. 1907/2006



# **Mometasone Ointment Formulation**

Version 2.2	Revision Date: 09.04.2021		DS Number: /58836-00009	Date of last issue: 10.10.2020 Date of first issue: 14.06.2017		
Mom	etasone:					
Bioaccumulation		:	<ul> <li>Species: Lepomis macrochirus (Bluegill sunfish)</li> <li>Bioconcentration factor (BCF): 107.1</li> <li>Method: OECD Test Guideline 305</li> </ul>			
Partition coefficient: n- octanol/water		:	log Pow: 4.68			
12.4 Mobi	ility in soil					
<u>Com</u>	ponents:					
Mom	etasone:					
	bution among environ- al compartments	:	log Koc: 4.02			
2.5 Resu	llts of PBT and vPvB a	sse	ssment			
Prod						
Assessment		:	This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.			
12.6 Endo	ocrine disrupting prope	ertie	S			
Prod	<u>uct:</u>					
Asse	ssment	:	ered to have enc REACH Article 5	hixture does not contain components consid- locrine disrupting properties according to 7(f) or Commission Delegated regulation or Commission Regulation (EU) 2018/605 a higher.		
12.7 Othe	r adverse effects					
No da	ata available					
	N 13: Disposal consi	dera	ations			
SECTIO						
SECTIO	-					
	te treatment methods			cordance with local regulations.		

## SECTION 14: Transport information

### 14.1 UN number or ID number

ADN

: UN 3077

according to Regulation (EC) No. 1907/2006



Versior 2.2	n Revision Date: 09.04.2021	SDS Number:Date of last issue: 10.10.20201758836-00009Date of first issue: 14.06.2017		
Δ	DR	: UN 3077		
RI		: UN 3077		
	IDG	: UN 3077		
	TA	: UN 3077		
	N proper shipping name			
	DN	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOL N.O.S. (Mometasone)	JD,	
AI	DR	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOL N.O.S. (Mometasone)	JD,	
RI	D	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOL N.O.S. (Mometasone)	JD,	
IN	IDG	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOL N.O.S. (Mometasone)	JD,	
IA	ТА	Environmentally hazardous substance, solid, n.o.s. (Mometasone)		
14.3 Tı	ansport hazard class(es)			
A	DN	: 9		
A	DR	: 9		
RI	D	: 9		
IN	IDG	: 9		
IA	ТА	: 9		
14.4 Pa	acking group			
Pa Cl Ha	<b>DN</b> acking group assification Code azard Identification Number abels	: III : M7 : 90 : 9		
Pa Cl Ha La	DR acking group assification Code azard Identification Number abels unnel restriction code	: III : M7 : 90 : 9 : (-)		
CI Ha	D acking group assification Code azard Identification Number abels	: III : M7 : 90 : 9		

according to Regulation (EC) No. 1907/2006



# **Mometasone Ointment Formulation**

Vers 2.2	sion	Revision Date: 09.04.2021		DS Number: 58836-00009	Date of last issue: 10.10.2020 Date of first issue: 14.06.2017
	IMDG Packing Labels EmS Co		:	III 9 F-A, S-F	
	IATA (Cargo) Packing instruction (cargo aircraft) Packing instruction (LQ) Packing group Labels			956 Y956 III Miscellaneous	
	Packing ger airc	g instruction (LQ)	: : : :	956 Y956 III Miscellaneous	
14.5	5 Enviro	nmental hazards			
	ADR	mentally hazardous	:	yes	
	Environmentally hazardous <b>RID</b> Environmentally hazardous <b>IMDG</b> Marine pollutant		:	yes yes	
			:	yes	
		Passenger) Imentally hazardous	:	yes	
446		Cargo) Imentally hazardous	:	yes	

### 14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

: Not applicable for product as supplied.

### 14.7 Maritime transport in bulk according to IMO instruments

- Remarks
- SECTION 15: Regulatory information

#### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances,	:	Not applicable
preparations and articles (Annex XVII)		
REACH - Candidate List of Substances of Very High	:	Not applicable
Concern for Authorisation (Article 59).		





Version 2.2	Revision Date: 09.04.2021	SDS Number: 1758836-00009		st issue: 10.10.20 st issue: 14.06.20		
	REACH - List of substances subject to authorisation : Not applicable (Annex XIV)					
Regu	Regulation (EC) No 1005/2009 on substances that de- : Not applicable plete the ozone layer					
Regu	Regulation (EU) 2019/1021 on persistent organic pollu- : Not applicable tants (recast)					
Regu ment	lation (EC) No 649/201 and the Council conce ngerous chemicals			ot applicable		
Seve	so III: Directive 2012/18 r-accident hazards invo					
E2		ENVIRONMEN HAZARDS	TAL	Quantity 1 200 t	Quantity 2 500 t	
The c	The components of this product are reported in the following inventories:					
AICS		: not determined				
DSL		: not determined				
IECS	С	: not determined				
<b>15.2 Chemical safety assessment</b> A Chemical Safety Assessment has not been carried out.						

TION 16: Other information	on	
Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
Full text of H-Statements		
H315	:	Causes skin irritation.
H319	:	Causes serious eye irritation.
H360Df	:	May damage the unborn child. Suspected of damaging fertili- ty.
H373	:	May cause damage to organs through prolonged or repeated exposure if inhaled.
H410	:	Very toxic to aquatic life with long lasting effects.
Full text of other abbreviatio	ons	
Aquatic Chronic	:	Long-term (chronic) aquatic hazard
Eye Irrit.	:	Eye irritation
Repr.	:	Reproductive toxicity
Skin Irrit.	:	Skin irritation
STOT RE	:	Specific target organ toxicity - repeated exposure
IE OEL	:	Ireland. List of Chemical Agents and Occupational Exposure Limit Values - Schedule 1
IE OEL / OELV - 8 hrs (TWA)	:	Occupational exposure limit value (8-hour reference period)
IE OEL / OELV - 15 min (STEL)	:	Occupational exposure limit value (15-minute reference peri- od)



# Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.2	09.04.2021	1758836-00009	Date of first issue: 14.06.2017

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways: ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN -Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS -Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP -Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL -International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS -Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to :	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data Sheet	eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/
Oneet	cy, mp.//ecila.eu/opa.eu/

Classification of the	mixture:	Classification procedure:
Skin Irrit. 2	H315	Calculation method
Eye Irrit. 2	H319	Calculation method
Aquatic Chronic 2	H411	Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

according to Regulation (EC) No. 1907/2006



# Mometasone Ointment Formulation

VersionRevision Date:SDS Number:Date of last issue: 10.10.20202.209.04.20211758836-00009Date of first issue: 14.06.2017